MDxHealth's third quarter confirmed that the company has moved from a growth story to a repair job. The urology diagnostics company reported a loss of $0.16 per share, well short of the -$0.07 consensus, a 128.6% miss. Revenue of $22.71 million missed the $28.5 million consensus by 20.3%. Earnings Whispers' normalized comparison shows earnings flat year over year and revenue down 17.2%. The release, however, re-presents prior-year figures to exclude the discontinued Resolve UTI business, and on that basis revenue was flat at $22.7 million in both periods. The roughly 17% decline is clearest sequentially, from $27.2 million in Q2. Either way, the conclusion is the same. Growth that management called a historic acceleration just one quarter ago has stalled, and the full-year outlook went with it.
The underlying numbers are worse than the per-share figure suggests. The IFRS loss per share narrowed to $0.16 from $0.20 only because the share count is larger. The net loss itself widened 26% to $12.3 million. Operating loss nearly doubled to $8.1 million, and operating expenses rose 16% as ExoDx costs, acquired in September 2025, sit on a revenue base that is no longer growing. Gross margin fell to 61.8% from 65.0% a year ago and 65.7% in Q2. The cause was test mix: tissue-based tests dropped to 79% of revenue from 92%, while lower-margin liquid-based ExoMDx volume rose. Tissue test volume fell 11% to 11,232. Adjusted EBITDA losses widened to $6.3 million, from $2.3 million in Q2 and $0.9 million a year earlier. Through nine months, adjusted EBITDA losses total $13.9 million against roughly breakeven in 2025. Even the company's preferred non-IFRS measure is now heading the wrong way.
The call explained the cause but offered little comfort. Sales-rep turnover "accelerated materially" through Q3, which management tied to fallout from the Resolve wind-down. In response, the company eliminated the Chief Commercial Officer role and split sales and marketing, with both now reporting directly to CEO Michael McGarrity. The shift in tone was stark. In August, management celebrated the largest quarter-over-quarter acceleration in company history and projected "linear-ish" gains through Q3 and Q4. Now it calls Q3 the nadir and expects Q4 revenue roughly in line with Q3. That makes the $110-115 million fiscal 2026 revenue guide unreachable. The company reaffirmed it as "meet or exceed" on the Q2 call, and that range had itself already been cut from $137-140 million. MDxHealth is now effectively in a no-guide position. It also abandoned the target of exiting 2026 at positive adjusted EBITDA, which had itself replaced an earlier 10% EBITDA-margin exit goal.
The recovery case rests on execution that has not yet happened. Management expects a fully staffed, trained sales force exiting Q4 and "linear acceleration" through 2027, with formal guidance early next year. New reps typically need one to two quarters to ramp, however, which pushes any visible rebound well into 2027. Other potential catalysts include:
- AI and digital-pathology initiatives targeted for the first half of 2027
- The Oxford PROTECT study
- Inbound partnership and tuck-in interest that management describes as intact
Against that, competition is building in GPS and active surveillance from AI-based entrants, and NCCN guideline language has changed.
The balance sheet is the pressure point. Cash of $31.7 million looks better than Q2's $19.2 million only because of a $20 million August raise. Pro forma for that raise, Q3 burn was roughly $7.5 million. Analysts on the call focused on runway and on the company's reliance on earn-out flexibility from Exact Sciences and Abbott and on its OrbiMed debt facility. That is not the conversation of a company with a stable financing position.
The market priced much of this in before the report. Shares opened at $0.61 after the August release and briefly spiked to $1.13 that day. They have since collapsed to $0.15, down 75.9% since that post-report open and 87% below the inter-earnings high. The stock trades about 89.5% below its $1.39 200-day moving average and sits just above the $0.14 52-week low set on November 10. The October preliminary update telegraphed the damage. Investor sentiment improved modestly, from -0.82 to -0.72, but remains deeply negative. That reads more as exhausted pessimism than renewed confidence.
The bottom line is that MDxHealth turned a credible rebound narrative into a commercial reset in a single quarter. Revenue has stalled, margins and EBITDA are deteriorating, and guidance has been withdrawn. The company now asks investors to trust a rebuilt sales force and 2027 catalysts while cash burn draws on a finite balance sheet. With the stock already near its lows, much of the bad news may be in the price. Still, until rehired reps produce sequential growth and management issues credible 2027 guidance, bears hold the stronger hand.